申请人:——
公开号:US05538988A1
公开(公告)日:1996-07-23
The present invention relates to novel benzocycloalkylazolethione compounds which are dopamine .beta.-hydroxylase inhibitors in which the benzocycloalkyl portion of the compound is selected from indanyl, 1,2,3,4-tetrahydronaphthalenyl and 6,7,8,9-tetrahydro-5H-benzocycloheptenyl (in which the benzo is optionally substituted with one to three substituents) and the azolethione portion of the compound is selected from 2-thioxo-2,3-dihydro-1H-imidazol-3-yl, 5-thioxo-4,5-dihydro-1H-[1,2,4]triazol-4-yl and 5-thioxo-4,5-dihydro-1H-[1,2,4]triazol-1-yl (each optionally substituted with one to three substituents); and the prodrugs, pharmaceutically acceptable salts, individual isomers and mixtures of isomers and the methods of using and preparing such benzocycloalkylazolethione compounds.
本发明涉及一种新型苯并环烷基唑硫酮化合物,它们是多巴胺β-羟化酶抑制剂,其中化合物的苯并环烷基部分选自吲哚基、1,2,3,4-四氢萘基和6,7,8,9-四氢-5H-苯并环庚基(其中苯并基可选择性地取代一个到三个取代基),化合物的唑硫酮部分选自2-硫代-2,3-二氢-1H-咪唑-3-基、5-硫代-4,5-二氢-1H-[1,2,4]三唑-4-基和5-硫代-4,5-二氢-1H-[1,2,4]三唑-1-基(每个可选择性地取代一个到三个取代基);以及这些苯并环烷基唑硫酮化合物的前药、药学上可接受的盐、各个异构体和异构体混合物的使用和制备方法。